Aktie A2P9GM EXACT THERAPEUTICS
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen EXACT Therapeutics

Aktien

A2P9GM

NO0010852213

EXTX

Realtime Oslo Bors
Andere Börsenplätze
 16:45:00 22.04.2024 		% 5 Tage % 1. Jan.
7 NOK 0.00% Intraday Chart für EXACT Therapeutics 0.00% -41.67%
19.04. EXACT Therapeutics AS meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
2023 EXACT Therapeutics AS meldet Ergebnis für das Halbjahr bis zum 30. Juni 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023
Additional promising clinical data from EXACT Therapeutics' ongoing ACTIVATE study presented at AACR Annual Meeting
EXACT Therapeutics to Present at 2024 American Association for Cancer Research (AACR) Annual Meeting
EXACT Therapeutics AS - Share capital increase registered
EXACT Therapeutics presenting at DNB Nordic Healthcare conference December 14
EXACT Therapeutics : announces successful placement of NOK 25 million share issue
EXACT Therapeutics AS: Primary insider notices
EXACT Therapeutics AS: Private placement successfully placed
EXACT Therapeutics AS: Contemplated Private Placement
Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study
EXACT Therapeutics receives regulatory approval to start recruitment of patients at Oslo University hospital
EXACT Therapeutics AS - Issuance of share options
EXACT Therapeutics CEO Dr Per Walday to participate in international Drug Delivery panel
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2023
EXACT Therapeutics : Interim Report 2023
EXACT Therapeutics announces first half 2023 interim results
EXACT Therapeutics announces appointment of Caspar Foghsgaard as SVP Commercial & Business Development
EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023
Exact Therapeutics Jumps 13% After Positive Outcomes From Acoustic Cluster Therapy Trial
EXACT Therapeutics announces positive clinical results from the ACTIVATE Phase I dose escalation
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2P9GM Aktie
  4. Nachrichten EXACT Therapeutics
  5. Andere Sprachen